Algorae Pharmaceuticals Limited has released a press release.
LCT exits peptide projects
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- LCT CEO Dr Ken Taylor signals intention to retire
- Preliminary Final Report and 2020 Financial Statements
- Amended Appendix 4C
- Response to ASX Aware Query
- Appendix 4C - quarterly
Later from Algorae Pharmaceuticals
- LCT Interim CEO Appointed
- Preliminary Final Report and 2021 Financial Statements
- Secures Funds for 3rd Trial of NTCELL in Parkinson Disease
- LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial
- LCT Advises Price Change for Rights Issue
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals